Factory Price Supply Nootropics Raw Material Idebenone Powder CAS 58186-27-9

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: 58186-27-9
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Solid
• Purity: >99%
• Product Name: Idebenone
• Assay: 99% Min
• Test: HPLC
• CAS: 58186-27-9
• Classification: Biochemical
• Shelf Life: 2 Years Proper Storage
• Transport Package: Dry and Cool
• Specification: 1kg/Bag, 25kg/Drum
• Trademark: Gina
• Origin: Shaanxi, China
• Production Capacity: 100000 Kilogram/ Month

Product Description

Idebenone is a synthetic variant of coenzyme Q10 (CoQ10), which initially developed for the treatment of Alzheimer's disease and other cognitive defects.Target: OthersIdebenone is a synthetic variant of coenzyme Q10 (CoQ10), which initially developed for the treatment of Alzheimer's disease and other cognitive defects. Idebenone was generally well tolerated with similar numbers of adverse events in each group. One child receiving high-dose idebenone developed neutropenia after 6 months, which resolved after discontinuation of treatment. 8OH2′dG concentrations were not increased, and did not significantly change with idebenone treatment [1]. The 2-year efficacy and safety of idebenone were studied in a prospective, randomized, double-blind multicentre study in 3 parallel groups of patients with dementia of the Alzheimer type (DAT) of mild to moderate degree. A total of 450 patients were randomized to either placebo for 12 months, followed by idebenone 90 mg tid for another 12 months (n = 153) or idebenone 90 mg tid for 24 months (n = 148) or 120 mg tid for 24 months (n = 149). idebenone showed statistically significant dose-dependent improvement in the primary efficacy variable ADAS-Total and in all the secondary efficacy variables [2].
 

Product Name	Idebenone
Appearance	Orange yellow or yellow, crystalline powder
Purity	99%
CAS No	58186-27-9
MF	C19H30O5
MW	338.4385

Function of Idebenone

Idebenone (trade names Catena, Raxone, Sovrima, among others) is a drug that was initially developed by Takeda Pharmaceutical Company for the treatment of Alzheimer's disease and other cognitive defects. This has been met with limited success. The Swiss company Santhera Pharmaceuticals has started to investigate it for the treatment of neuromuscular diseases. In 2010, early clinical trials for the treatment of Friedreich's ataxia and Duchenne muscular dystrophy have been completed. As of December 2013[update] the drug is not approved for these indications in North America or Europe, but it is approved for the treatment of Leber's hereditary optic neuropathy (LHON) in Europe. Chemically, idebenone is an organic compound of the quinone family. It is also promoted commercially as a synthetic analog of coenzyme Q10 (CoQ10)..

Application of Idebenone

Damage to brain function caused by chronic cerebrovascular disease and brain trauma caused by idbenzoquinone. can improve subjective symptoms, language, anxiety, depression, memory loss, intelligence decline and other mental behavior disorders. .